Article Details
Retrieved on: 2022-06-04 13:08:31
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Updated results from the ELEVATE-TN Phase III trial showed AstraZeneca's Calquence (acalabrutinib) maintained a statistically significant.
Article found on: www.miragenews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here